Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)Citation formats

  • External authors:
  • J. Galloway
  • A. Ustianowski

Standard

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). / Dixon, W. G.; Hyrich, K. L.; Watson, K. D.; Lunt, M.; Galloway, J.; Ustianowski, A.; Symmons, D. P M.

In: Annals of the rheumatic diseases, Vol. 69, No. 3, 03.2010, p. 522-528.

Research output: Contribution to journal › Article › peer-review

Harvard

Dixon, WG, Hyrich, KL, Watson, KD, Lunt, M, Galloway, J, Ustianowski, A & Symmons, DPM 2010, 'Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)', Annals of the rheumatic diseases, vol. 69, no. 3, pp. 522-528. https://doi.org/10.1136/ard.2009.118935

APA

Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010). Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the rheumatic diseases, 69(3), 522-528. https://doi.org/10.1136/ard.2009.118935

Vancouver

Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the rheumatic diseases. 2010 Mar;69(3):522-528. https://doi.org/10.1136/ard.2009.118935

Author

Dixon, W. G. ; Hyrich, K. L. ; Watson, K. D. ; Lunt, M. ; Galloway, J. ; Ustianowski, A. ; Symmons, D. P M. / Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). In: Annals of the rheumatic diseases. 2010 ; Vol. 69, No. 3. pp. 522-528.

Bibtex

@article{d7bc330190b1485f860f96f3b379c225,
title = "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)",
abstract = "Background: The risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) is thought to be increased following anti-tumour necrosis factor (anti-TNF) therapy, with a proposed differential risk between the anti-TNF drugs etanercept (ETA), infliximab (INF) and adalimumab (ADA). Objective: To compare directly the risk between drugs, to explore time to event, site of infection and the role of ethnicity. Methods: Data from the British Society for Rheumatology Biologics Register (BSRBR), a national prospective observational study, were used to compare TB rates in 10 712 anti-TNF treated patients (3913 ETA, 3295 INF, 3504 ADA) and 3232 patients with active RA treated with traditional disease-modifying antirheumatic drugs. Results: To April 2008, 40 cases of TB were reported, all in the anti-TNF cohort. The rate of TB was higher for the monoclonal antibodies ADA (144 events/100 000 person-years) and INF (136/100 000 person-years) than for ETA (39/100 000 person-years). After adjustment, the incidence rate ratio compared with ETA-treated patients was 3.1 (95% CI 1.0 to 9.5) for INF and 4.2 (1.4 to 12.4) for ADA. The median time to event was lowest for INF (5.5 months) compared with ETA (13.4 months) and ADA (18.5 months). 13/40 cases occurred after stopping treatment. 25/40 (62%) cases were extrapulmonary, of which 11 were disseminated. Patients of non-white ethnicity had a sixfold increased risk of TB compared with white patients treated with anti-TNF therapy. Conclusion: The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.",
author = "Dixon, {W. G.} and Hyrich, {K. L.} and Watson, {K. D.} and M. Lunt and J. Galloway and A. Ustianowski and Symmons, {D. P M}",
year = "2010",
month = mar,
doi = "10.1136/ard.2009.118935",
language = "English",
volume = "69",
pages = "522--528",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ ",
number = "3",

}

RIS

TY - JOUR

T1 - Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)

AU - Dixon, W. G.

AU - Hyrich, K. L.

AU - Watson, K. D.

AU - Lunt, M.

AU - Galloway, J.

AU - Ustianowski, A.

AU - Symmons, D. P M

PY - 2010/3

Y1 - 2010/3

N2 - Background: The risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) is thought to be increased following anti-tumour necrosis factor (anti-TNF) therapy, with a proposed differential risk between the anti-TNF drugs etanercept (ETA), infliximab (INF) and adalimumab (ADA). Objective: To compare directly the risk between drugs, to explore time to event, site of infection and the role of ethnicity. Methods: Data from the British Society for Rheumatology Biologics Register (BSRBR), a national prospective observational study, were used to compare TB rates in 10 712 anti-TNF treated patients (3913 ETA, 3295 INF, 3504 ADA) and 3232 patients with active RA treated with traditional disease-modifying antirheumatic drugs. Results: To April 2008, 40 cases of TB were reported, all in the anti-TNF cohort. The rate of TB was higher for the monoclonal antibodies ADA (144 events/100 000 person-years) and INF (136/100 000 person-years) than for ETA (39/100 000 person-years). After adjustment, the incidence rate ratio compared with ETA-treated patients was 3.1 (95% CI 1.0 to 9.5) for INF and 4.2 (1.4 to 12.4) for ADA. The median time to event was lowest for INF (5.5 months) compared with ETA (13.4 months) and ADA (18.5 months). 13/40 cases occurred after stopping treatment. 25/40 (62%) cases were extrapulmonary, of which 11 were disseminated. Patients of non-white ethnicity had a sixfold increased risk of TB compared with white patients treated with anti-TNF therapy. Conclusion: The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.

AB - Background: The risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) is thought to be increased following anti-tumour necrosis factor (anti-TNF) therapy, with a proposed differential risk between the anti-TNF drugs etanercept (ETA), infliximab (INF) and adalimumab (ADA). Objective: To compare directly the risk between drugs, to explore time to event, site of infection and the role of ethnicity. Methods: Data from the British Society for Rheumatology Biologics Register (BSRBR), a national prospective observational study, were used to compare TB rates in 10 712 anti-TNF treated patients (3913 ETA, 3295 INF, 3504 ADA) and 3232 patients with active RA treated with traditional disease-modifying antirheumatic drugs. Results: To April 2008, 40 cases of TB were reported, all in the anti-TNF cohort. The rate of TB was higher for the monoclonal antibodies ADA (144 events/100 000 person-years) and INF (136/100 000 person-years) than for ETA (39/100 000 person-years). After adjustment, the incidence rate ratio compared with ETA-treated patients was 3.1 (95% CI 1.0 to 9.5) for INF and 4.2 (1.4 to 12.4) for ADA. The median time to event was lowest for INF (5.5 months) compared with ETA (13.4 months) and ADA (18.5 months). 13/40 cases occurred after stopping treatment. 25/40 (62%) cases were extrapulmonary, of which 11 were disseminated. Patients of non-white ethnicity had a sixfold increased risk of TB compared with white patients treated with anti-TNF therapy. Conclusion: The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.

U2 - 10.1136/ard.2009.118935

DO - 10.1136/ard.2009.118935

M3 - Article

C2 - 19854715

VL - 69

SP - 522

EP - 528

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

SN - 0003-4967

IS - 3

ER -